In The News: School of Integrated Health Sciences
The proposed guideline would give all astronauts the same radiation limit, regardless of age and sex.
A blue-ribbon panel has endorsed NASA’s plans to revise its standard for exposing astronauts to radiation in a way that would allow women to spend more time in space.
A blue-ribbon panel has endorsed NASA’s plans to revise its standard for exposing astronauts to radiation in a way that would allow women to spend more time in space.
The FDA’s approval of Biogen’s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen.
Now that the FDA has approved Biogen's aducanumab (Aduhelm), the controversial new drug for Alzheimer's disease, what does this mean?
In a watershed moment for the field, the U.S. Food and Drug Administration yesterday approved the first Alzheimer’s treatment that tackles the underlying disease pathology.
The first drug to treat Alzheimer’s disease in 18 years, which was extensively researched at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, has won approval from the Food and Drug Administration.
The Food and Drug Administration (FDA) approved Biogen's aducanumab on June 7, making it the first Alzheimer's medication available in nearly 20 years and the only one that could slow the progression of the disease.
For the first time in nearly 20 years, the FDA approved a drug for the treatment of Alzheimer's disease.
For the first time in nearly 20 years, the FDA approved a drug for the treatment of Alzheimer's disease.
Telephones were ringing off the hook Monday at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, with patients calling to inquire about the U.S. Food and Drug Administration’s approval of a drug designed to slow the progression of Alzheimer’s disease.
For the first time, the US FDA has approved a drug that is supposed to counteract a cause of Alzheimer's disease. But it is highly controversial.